AR002932A1 - Solucion acuosa de interferon - Google Patents

Solucion acuosa de interferon

Info

Publication number
AR002932A1
AR002932A1 ARP960102079A AR10207996A AR002932A1 AR 002932 A1 AR002932 A1 AR 002932A1 AR P960102079 A ARP960102079 A AR P960102079A AR 10207996 A AR10207996 A AR 10207996A AR 002932 A1 AR002932 A1 AR 002932A1
Authority
AR
Argentina
Prior art keywords
interferon solution
aqueous interferon
aqueous
interferon
solution
Prior art date
Application number
ARP960102079A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR002932A1 publication Critical patent/AR002932A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
ARP960102079A 1995-04-06 1996-04-03 Solucion acuosa de interferon AR002932A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95105166 1995-04-06

Publications (1)

Publication Number Publication Date
AR002932A1 true AR002932A1 (es) 1998-05-27

Family

ID=8219166

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102079A AR002932A1 (es) 1995-04-06 1996-04-03 Solucion acuosa de interferon

Country Status (32)

Country Link
US (1) US5762923A (fr)
EP (1) EP0736303B1 (fr)
JP (1) JP2758154B2 (fr)
KR (1) KR100212346B1 (fr)
CN (1) CN1066065C (fr)
AR (1) AR002932A1 (fr)
AT (1) ATE183650T1 (fr)
AU (1) AU685356B2 (fr)
BR (1) BR9601276A (fr)
CA (1) CA2172664C (fr)
CO (1) CO4750807A1 (fr)
CY (1) CY2194B1 (fr)
CZ (1) CZ287626B6 (fr)
DE (1) DE69603894T2 (fr)
DK (1) DK0736303T3 (fr)
ES (1) ES2136910T3 (fr)
GR (1) GR3031775T3 (fr)
HK (1) HK1012232A1 (fr)
HU (1) HU227643B1 (fr)
IL (1) IL117752A (fr)
MA (1) MA23838A1 (fr)
MY (1) MY113594A (fr)
NO (1) NO316801B1 (fr)
NZ (1) NZ286300A (fr)
PE (1) PE38897A1 (fr)
PL (1) PL183873B1 (fr)
RU (1) RU2113845C1 (fr)
SA (1) SA96160728B1 (fr)
SG (1) SG52806A1 (fr)
TR (1) TR199600287A2 (fr)
TW (1) TW426523B (fr)
ZA (1) ZA962553B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
SK284989B6 (sk) * 1996-12-24 2006-04-06 Biogen, Inc. Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
PT1066059E (pt) * 1998-03-26 2005-10-31 Schering Corp Formulacoes para proteccao de conjugados de peg-interferao alfa
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
AU3473999A (en) * 1998-04-03 1999-10-25 Chiron Corporation Injectable igf-formulations containing succinate as buffering agent
JP5281726B2 (ja) 1998-05-15 2013-09-04 メルク・シャープ・アンド・ドーム・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法
PL192364B1 (pl) * 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
WO2000004913A1 (fr) * 1998-07-23 2000-02-03 Eli Lilly And Company Formulations de fsh et de variants de fsh, produits et procedes
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
ES2404074T3 (es) 1998-08-06 2013-05-23 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
CA2356010A1 (fr) * 1998-12-22 2000-06-29 Schering Corporation Traitement des infections du virus de l'hepatite c avec interleukine-10
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
AU771569B2 (en) 1999-04-08 2004-03-25 Merck Sharp & Dohme Corp. Melanoma therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
EP1278544A4 (fr) 2000-04-12 2004-08-18 Human Genome Sciences Inc Proteines hybrides d'albumine
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
HU228583B1 (en) 2000-11-07 2013-04-29 Novartis Vaccines & Diagnostic Stabilized interferon compositions
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
JP2002265383A (ja) * 2001-03-14 2002-09-18 Mitsubishi Pharma Corp インターフェロンα注射用液状製剤
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2002083165A1 (fr) * 2001-04-10 2002-10-24 Sumitomo Pharmaceuticals Co., Ltd. Preparations stables destinees a etre injectees
LT4947B (lt) 2001-09-26 2002-08-26 Biotechnologijos Institutas Interferono alfa farmacinė kompozicija
EP2277910A1 (fr) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Protéines de fusion d'albumine
IL162796A0 (en) 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
AU2004226666B9 (en) 2003-04-02 2010-04-08 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
SI1638595T1 (sl) 2003-06-20 2013-04-30 Ares Trading S.A. Liofilizirane formulacije fsh/lh
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
AR045258A1 (es) * 2003-08-21 2005-10-19 Altana Pharma Ag Un producto farmaceutico para inyeccion
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
CA2553040A1 (fr) 2004-02-02 2005-08-18 Ambrx, Inc. Polypeptides a faisceau a quatre helices (4hb) humains modifies, et leur utilisation
EA012205B1 (ru) 2004-05-17 2009-08-28 Арес Трейдинг С.А. Гидрогелевые препараты интерферона
BRPI0510526A (pt) 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
CA2567309A1 (fr) * 2004-06-01 2005-12-15 Ares Trading S.A. Procede de stabilisation de proteines
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
CN101022822B (zh) 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
ES2302402B1 (es) 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2008026044A2 (fr) * 2006-08-31 2008-03-06 Wockhardt Research Centre Compositions pharmaceutiques de bupropion
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
WO2008145323A1 (fr) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant des interférons
ES2386575T3 (es) * 2007-09-04 2012-08-23 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2a modificado por polietilenglicol, su proceso de síntesis y su aplicación
PL2186830T3 (pl) * 2007-09-04 2012-09-28 Biosteed Gene Expression Tech Co Ltd Interferon alfa 2b zmodyfikowany glikolem polietylenowym, jego wytwarzanie i zastosowanie
WO2009055343A2 (fr) * 2007-10-22 2009-04-30 Schering Corporation Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
SI2234645T1 (sl) 2007-12-20 2012-07-31 Merck Serono Sa Formulacije peg interferon beta
EP2305309A2 (fr) 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugués pour l'administration de composés biologiquement actifs
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
EP3482768A1 (fr) 2009-06-25 2019-05-15 Horizon Pharma Rheumatology LLC Procédés et kits pour prédire le risque de réaction de perfusion et perte induite par anticorps de la réponse par surveillance de l'acide urique sérique pendant une thérapie uricase pégylée
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
RU2447083C1 (ru) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102526758B (zh) * 2012-02-23 2013-02-13 北京三元基因工程有限公司 一种聚乙二醇化干扰素稳定的水溶液
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP6445169B2 (ja) * 2014-09-23 2018-12-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ α型インターフェロンを含有する安定したベンジルアルコールフリーの水溶液製剤
RU2768656C1 (ru) * 2021-09-10 2022-03-24 Илья Александрович Марков Противовирусное средство в жидкой форме и способ его приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物
EP0284249A1 (fr) * 1987-03-13 1988-09-28 Interferon Sciences, Inc. Composition lyophilisée de lymphokine
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0396777A4 (en) * 1988-11-14 1991-03-13 Otsuka Pharmaceutical Co., Ltd. Interferon preparation for nasal administration
JPH0651642B2 (ja) * 1988-11-14 1994-07-06 大塚製薬株式会社 インターフェロン経鼻投与用製剤
CA2033714A1 (fr) * 1990-01-25 1991-07-26 Alberto Ferro Preparations pharmaceutiques
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
IL109350A (en) * 1993-05-12 2001-01-28 Genentech Inc Stable liquid preparations of gamma interferon

Also Published As

Publication number Publication date
HUP9600857A2 (en) 1997-08-28
CZ99496A3 (en) 1996-10-16
HK1012232A1 (en) 1999-07-30
CY2194B1 (en) 2002-11-08
ES2136910T3 (es) 1999-12-01
ZA962553B (en) 1996-10-07
NO316801B1 (no) 2004-05-18
TW426523B (en) 2001-03-21
DE69603894T2 (de) 2000-04-20
US5762923A (en) 1998-06-09
SA96160728B1 (ar) 2005-05-04
TR199600287A2 (tr) 1997-03-21
CA2172664C (fr) 2000-10-03
PL183873B1 (pl) 2002-07-31
CZ287626B6 (en) 2001-01-17
JPH08283176A (ja) 1996-10-29
CN1141808A (zh) 1997-02-05
AU5044696A (en) 1996-10-17
IL117752A0 (en) 1996-08-04
CA2172664A1 (fr) 1996-10-07
EP0736303A2 (fr) 1996-10-09
PE38897A1 (es) 1997-10-04
EP0736303B1 (fr) 1999-08-25
CO4750807A1 (es) 1999-03-31
HU9600857D0 (en) 1996-05-28
NZ286300A (en) 1997-05-26
RU2113845C1 (ru) 1998-06-27
PL313655A1 (en) 1996-10-14
SG52806A1 (en) 1998-09-28
MY113594A (en) 2002-04-30
IL117752A (en) 2000-11-21
AU685356B2 (en) 1998-01-15
KR100212346B1 (ko) 1999-08-02
DK0736303T3 (da) 2000-01-10
HU227643B1 (en) 2011-10-28
HUP9600857A3 (en) 1998-01-28
NO961322L (no) 1996-10-07
BR9601276A (pt) 1998-01-13
EP0736303A3 (fr) 1997-02-26
DE69603894D1 (de) 1999-09-30
NO961322D0 (no) 1996-04-01
CN1066065C (zh) 2001-05-23
GR3031775T3 (en) 2000-02-29
MA23838A1 (fr) 1996-12-31
JP2758154B2 (ja) 1998-05-28
ATE183650T1 (de) 1999-09-15
KR960037063A (ko) 1996-11-19

Similar Documents

Publication Publication Date Title
AR002932A1 (es) Solucion acuosa de interferon
GT199800126A (es) Terapia de combinacion.
YU47204B (sh) Derivati didehidro-vitamina d3
ES2183023T3 (es) Composicion farmaceutica estabilizada con un agente basico.
AR053946A2 (es) Variante de alfa-amilasa de bacillus stearothermophilus original
MX9306499A (es) Composiciones farmaceuticas que contienen una anfetamina.
CO5011037A1 (es) Metodo para mejorar la condicion de la piel de un usuario en el area cubierta por un articulo absorbente
ES2195970T3 (es) L-ribavirina y usos de la misma.
CA2016699A1 (fr) Agents lytiques et leurs usages
AR000714A1 (es) Un metodo de uso de un agente quelante para mejorar la fidelidad de color de telas lavadas y una composicion para uso en dicho metodo.
AR023529A1 (es) Una composicion champu acondicionadora del cabello y un metodo para acondicionar el cabello
MX9302268A (es) Composiciones blanqueadoras liquidas acuosas con agente blanqueador fluorecente y polivinilpirrolidona o alcohol polivinilico.
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
ES2191417T3 (es) Composicion desinfectante.
BR9610930A (pt) Composição depilatória incluindo uma quantidade funcional de um agente tixoitrópico, e, uso da quantidade funcional de um agente tixotrópico.
ES2132539T3 (es) Composiciones insecticidas sinergicas.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
MX9303913A (es) Composiciones detergentes liquidas acuosas concentradas que comprenden polivinilpirrolidona y un polimero de liberacion de suciedad basado en tereftalato.
ES2033262T3 (es) Composicion esterilizante a base de glutaraldehido de actividad antibacteriana y antimicotica, en un vehiculo acuoso.
ES2129835T3 (es) Purificacion de propofol.
DE69423402D1 (de) Stabile, pharmazeutische Zusammensetzungen die hybrid alpha-Interferon enthalten
RS49520B (sr) Antimikrobno aktivne smeše
UY24201A1 (es) Solución de interferón
ECSP961713A (es) Solucion de interferon
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.